Twenty-five actively serving male Canadian Special Operations Forces personnel with at least 16 years of breaching and explosives experience showed significantly higher uptake of the tau tracer [18F]flortaucipir in the frontal and temporal cortices than 10 age-matched Canadian Armed Forces controls with minimal blast exposure, according to a cross-sectional study published in Brain Communications on 3 March 2026. Voxelwise mapping identified clusters of elevated tracer signal in 88 percent of the exposed personnel, with nearly half of the clusters in the frontal cortex. The authors, led by Shamantha J. Lora and Shawn G. Rhind with senior author Isabelle Boileau of the Centre for Addiction and Mental Health in Toronto, reported that the PET signal tracked cumulative years of breaching, post-concussive symptoms, sleep disturbance and a measure of duty readiness, and that plasma markers including brain-derived tau, glial fibrillary acidic protein and neurofilament light were higher in the exposed group. The study scanned each participant once; it cannot show whether the signal came before or after the exposure, or where it goes next.
A companion paper in the same issue, from a Massachusetts General Hospital group led by Chieh-En Jane Tseng and Nicole R. Zurcher, scanned 28 active-duty US Special Operations Forces personnel with a different tracer, [18F]MK6240, which binds paired helical filament tau. Higher blood total tau was associated with higher tracer uptake in the left temporal cortex, parahippocampal gyrus and hippocampus, and higher blood tau and p-tau181 were associated with slower, less accurate performance on one visual memory task. The same group notes in that paper that its earlier pilot of 30 US operators found no association between cumulative blast exposure and either blood tau markers or regional MK6240 signal. Both authors describe their evidence as preliminary.
The honest counterweight arrived on 24 April 2026, when the Journal of Neurotrauma published a study of 422 service members and veterans enrolled in a Defense and Veterans Brain Injury Center longitudinal study, led by Sara M. Lippa. Participants were grouped by self-reported lifetime blast exposure (none, 93; low, 136; medium, 71; high, 122) and compared on five blood markers: GFAP, UCH-L1, neurofilament light, tau and phosphorylated tau. Its title states the finding plainly: blast exposure did not increase blood biomarkers of neurodegeneration. The populations differ, and so do the measures: the Canadian and US studies imaged small groups of career breachers with documented occupational overpressure, while the larger study relied on a single self-report question in a broader military sample.
The prevention stake is occupational, not pharmaceutical. The US Army has reported that a Defense Department policy memorandum signed on 8 August 2024 set requirements covering standoff distances for specific weapons systems, limits on firing excess rounds beyond training needs, and tracking of personnel blast overpressure exposure. Imaging studies of this size cannot set a dose limit; the Brain Communications authors call for wearable overpressure dosimeters to build exposure-response models, and caution that flortaucipir has known off-target binding, including to monoamine oxidase-B in the choroid plexus and basal ganglia.